Octreotide
Fat LossFDA-approved somatostatin analogEstablished
FDA-approved octapeptide somatostatin analog for acromegaly, neuroendocrine tumors, and VIPoma diarrhea.
For research use only.
Key Facts
- CAS
- 83150-76-9
- Molecular Weight (MW)
- 1019.3 g/mol
- Half-life
- ~1.7 hours (sc); depot has prolonged release
- Unit
- mcg
- Administration Route
- Subcutaneous / Intramuscular (LAR)
- Frequency
- Three times daily (immediate-release) or monthly (LAR)
- Last updated
- 8/23/2026
- Targets
- SSTR2SSTR5
Overview
FDA-approved octapeptide somatostatin analog for acromegaly, neuroendocrine tumors, and VIPoma diarrhea.
Protocol
- Dosage Range
- 50-200 mcg three times daily (immediate-release) or 10-30 mg monthly (LAR depot)
- Frequency
- Three times daily (immediate-release) or monthly (LAR)
- Cycle
- Long-term use as prescribed
- Administration Route
- Subcutaneous / Intramuscular (LAR)
- Reconstitution Guide
- LAR formulation requires reconstitution per package insert
Science
Mechanism of Action
Agonist at SSTR2/SSTR5 that suppresses GH, insulin, glucagon, and gut peptides and reduces splanchnic blood flow.
Targets
SSTR2SSTR5
Studies
- Octreotide in acromegaly— Journal/year not available
Benefits
Labeled NET / acromegaly therapySecretory-diarrhea control
Potential Side Effects
- Gallstones
- Hyperglycemia or hypoglycemia
- GI cramps
- Injection-site pain
References
- FDA label — SandostatinExternal link · Year —